Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.
This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.
The global Recombinant Human EGF market was valued at US$ 10300 million in 2023 and is anticipated to reach US$ 19500 million by 2030, witnessing a CAGR of 9.5% during the forecast period 2024-2030.
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.
This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.
The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell 鈥� a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR 鈥� that ultimately lead to DNA synthesis and cell proliferation.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human EGF, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human EGF.
Report Scope
The Recombinant Human EGF market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human EGF market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human EGF companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
Segment by Type
鈮�98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Segment by Application
Scientific Research
Medical Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human EGF companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Recombinant Human EGF 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 鈮�98% SDS-PAGE
1.2.3 95%-98% SDS-PAGE
1.2.4 <95% SDS-PAGE
1.3 麻豆原创 by Application
1.3.1 Global Recombinant Human EGF 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Scientific Research
1.3.3 Medical Drug
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Human EGF 麻豆原创 Perspective (2019-2030)
2.2 Recombinant Human EGF Growth Trends by Region
2.2.1 Global Recombinant Human EGF 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Human EGF Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Recombinant Human EGF Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Recombinant Human EGF 麻豆原创 Dynamics
2.3.1 Recombinant Human EGF Industry Trends
2.3.2 Recombinant Human EGF 麻豆原创 Drivers
2.3.3 Recombinant Human EGF 麻豆原创 Challenges
2.3.4 Recombinant Human EGF 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Human EGF Players by Revenue
3.1.1 Global Top Recombinant Human EGF Players by Revenue (2019-2024)
3.1.2 Global Recombinant Human EGF Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Recombinant Human EGF 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Human EGF Revenue
3.4 Global Recombinant Human EGF 麻豆原创 Concentration Ratio
3.4.1 Global Recombinant Human EGF 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Human EGF Revenue in 2023
3.5 Recombinant Human EGF Key Players Head office and Area Served
3.6 Key Players Recombinant Human EGF Product Solution and Service
3.7 Date of Enter into Recombinant Human EGF 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Human EGF Breakdown Data by Type
4.1 Global Recombinant Human EGF Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Recombinant Human EGF Forecasted 麻豆原创 Size by Type (2025-2030)
5 Recombinant Human EGF Breakdown Data by Application
5.1 Global Recombinant Human EGF Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Recombinant Human EGF Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Human EGF 麻豆原创 Size (2019-2030)
6.2 North America Recombinant Human EGF 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
6.4 North America Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Human EGF 麻豆原创 Size (2019-2030)
7.2 Europe Recombinant Human EGF 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
7.4 Europe Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Human EGF 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Recombinant Human EGF 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Human EGF 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Human EGF 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Human EGF 麻豆原创 Size (2019-2030)
9.2 Latin America Recombinant Human EGF 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Human EGF 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Recombinant Human EGF 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Human EGF 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Human EGF 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 FUJIFILM Irvine Scientific
11.1.1 FUJIFILM Irvine Scientific Company Detail
11.1.2 FUJIFILM Irvine Scientific Business Overview
11.1.3 FUJIFILM Irvine Scientific Recombinant Human EGF Introduction
11.1.4 FUJIFILM Irvine Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.1.5 FUJIFILM Irvine Scientific Recent Development
11.2 PeproTech, Inc
11.2.1 PeproTech, Inc Company Detail
11.2.2 PeproTech, Inc Business Overview
11.2.3 PeproTech, Inc Recombinant Human EGF Introduction
11.2.4 PeproTech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.2.5 PeproTech, Inc Recent Development
11.3 R&D Systems (Bio-Techne)
11.3.1 R&D Systems (Bio-Techne) Company Detail
11.3.2 R&D Systems (Bio-Techne) Business Overview
11.3.3 R&D Systems (Bio-Techne) Recombinant Human EGF Introduction
11.3.4 R&D Systems (Bio-Techne) Revenue in Recombinant Human EGF Business (2019-2024)
11.3.5 R&D Systems (Bio-Techne) Recent Development
11.4 Miltenyi Biotec
11.4.1 Miltenyi Biotec Company Detail
11.4.2 Miltenyi Biotec Business Overview
11.4.3 Miltenyi Biotec Recombinant Human EGF Introduction
11.4.4 Miltenyi Biotec Revenue in Recombinant Human EGF Business (2019-2024)
11.4.5 Miltenyi Biotec Recent Development
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Detail
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Recombinant Human EGF Introduction
11.5.4 Thermo Fisher Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.5.5 Thermo Fisher Scientific Recent Development
11.6 Abcam PLC
11.6.1 Abcam PLC Company Detail
11.6.2 Abcam PLC Business Overview
11.6.3 Abcam PLC Recombinant Human EGF Introduction
11.6.4 Abcam PLC Revenue in Recombinant Human EGF Business (2019-2024)
11.6.5 Abcam PLC Recent Development
11.7 BioLegend Way
11.7.1 BioLegend Way Company Detail
11.7.2 BioLegend Way Business Overview
11.7.3 BioLegend Way Recombinant Human EGF Introduction
11.7.4 BioLegend Way Revenue in Recombinant Human EGF Business (2019-2024)
11.7.5 BioLegend Way Recent Development
11.8 STEMCELL Technologies
11.8.1 STEMCELL Technologies Company Detail
11.8.2 STEMCELL Technologies Business Overview
11.8.3 STEMCELL Technologies Recombinant Human EGF Introduction
11.8.4 STEMCELL Technologies Revenue in Recombinant Human EGF Business (2019-2024)
11.8.5 STEMCELL Technologies Recent Development
11.9 Eurofins DiscoverX
11.9.1 Eurofins DiscoverX Company Detail
11.9.2 Eurofins DiscoverX Business Overview
11.9.3 Eurofins DiscoverX Recombinant Human EGF Introduction
11.9.4 Eurofins DiscoverX Revenue in Recombinant Human EGF Business (2019-2024)
11.9.5 Eurofins DiscoverX Recent Development
11.10 RayBiotech, Inc
11.10.1 RayBiotech, Inc Company Detail
11.10.2 RayBiotech, Inc Business Overview
11.10.3 RayBiotech, Inc Recombinant Human EGF Introduction
11.10.4 RayBiotech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.10.5 RayBiotech, Inc Recent Development
11.11 Prospec-Tany
11.11.1 Prospec-Tany Company Detail
11.11.2 Prospec-Tany Business Overview
11.11.3 Prospec-Tany Recombinant Human EGF Introduction
11.11.4 Prospec-Tany Revenue in Recombinant Human EGF Business (2019-2024)
11.11.5 Prospec-Tany Recent Development
11.12 Tonbo Biosciences
11.12.1 Tonbo Biosciences Company Detail
11.12.2 Tonbo Biosciences Business Overview
11.12.3 Tonbo Biosciences Recombinant Human EGF Introduction
11.12.4 Tonbo Biosciences Revenue in Recombinant Human EGF Business (2019-2024)
11.12.5 Tonbo Biosciences Recent Development
11.13 EnQuire Bio
11.13.1 EnQuire Bio Company Detail
11.13.2 EnQuire Bio Business Overview
11.13.3 EnQuire Bio Recombinant Human EGF Introduction
11.13.4 EnQuire Bio Revenue in Recombinant Human EGF Business (2019-2024)
11.13.5 EnQuire Bio Recent Development
11.14 ScienCell Research Laboratories
11.14.1 ScienCell Research Laboratories Company Detail
11.14.2 ScienCell Research Laboratories Business Overview
11.14.3 ScienCell Research Laboratories Recombinant Human EGF Introduction
11.14.4 ScienCell Research Laboratories Revenue in Recombinant Human EGF Business (2019-2024)
11.14.5 ScienCell Research Laboratories Recent Development
11.15 BioVision, Inc
11.15.1 BioVision, Inc Company Detail
11.15.2 BioVision, Inc Business Overview
11.15.3 BioVision, Inc Recombinant Human EGF Introduction
11.15.4 BioVision, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.15.5 BioVision, Inc Recent Development
11.16 Abm Inc
11.16.1 Abm Inc Company Detail
11.16.2 Abm Inc Business Overview
11.16.3 Abm Inc Recombinant Human EGF Introduction
11.16.4 Abm Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.16.5 Abm Inc Recent Development
11.17 Cell Guidance Systems
11.17.1 Cell Guidance Systems Company Detail
11.17.2 Cell Guidance Systems Business Overview
11.17.3 Cell Guidance Systems Recombinant Human EGF Introduction
11.17.4 Cell Guidance Systems Revenue in Recombinant Human EGF Business (2019-2024)
11.17.5 Cell Guidance Systems Recent Development
11.18 Creative BioMart
11.18.1 Creative BioMart Company Detail
11.18.2 Creative BioMart Business Overview
11.18.3 Creative BioMart Recombinant Human EGF Introduction
11.18.4 Creative BioMart Revenue in Recombinant Human EGF Business (2019-2024)
11.18.5 Creative BioMart Recent Development
11.19 Sino Biological
11.19.1 Sino Biological Company Detail
11.19.2 Sino Biological Business Overview
11.19.3 Sino Biological Recombinant Human EGF Introduction
11.19.4 Sino Biological Revenue in Recombinant Human EGF Business (2019-2024)
11.19.5 Sino Biological Recent Development
11.20 Cell Sciences
11.20.1 Cell Sciences Company Detail
11.20.2 Cell Sciences Business Overview
11.20.3 Cell Sciences Recombinant Human EGF Introduction
11.20.4 Cell Sciences Revenue in Recombinant Human EGF Business (2019-2024)
11.20.5 Cell Sciences Recent Development
11.21 Axol Bioscience
11.21.1 Axol Bioscience Company Detail
11.21.2 Axol Bioscience Business Overview
11.21.3 Axol Bioscience Recombinant Human EGF Introduction
11.21.4 Axol Bioscience Revenue in Recombinant Human EGF Business (2019-2024)
11.21.5 Axol Bioscience Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
听
听
*If Applicable.
